Conclusions
On admission, high-dose rosuvastatin therapy reduced CI-AKI occurrence and improved short-term clinical outcome in statin-naïve patients with NSTE-ACS scheduled for early invasive strategy.
Rosuvastatin for Contrast-Induced Nephropathy in ACS
Rosuvastatin for Contrast-Induced Nephropathy in ACS
On admission, high-dose rosuvastatin therapy reduced CI-AKI occurrence and improved short-term clinical outcome in statin-naïve patients with NSTE-ACS scheduled for early invasive strategy.
On admission, high-dose rosuvastatin therapy reduced CI-AKI occurrence and improved short-term clinical outcome in statin-naïve patients with NSTE-ACS scheduled for early invasive strategy.